Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas. The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte. Ltd. (Enleofen), with a goal to improve patient outcomes.
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues. It can be triggered by different factors (such as infections, inflammation, autoimmune disorders, degenerative diseases, tumors, and injury), can cause organ dysfunction/failure, and affect the quality of life and survival of patients. Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis. Current treatments have led to progress in some areas, however fibrotic diseases remain to be a leading cause of morbidity/mortality and account for more than one third of deaths worldwide.
IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
“The initiation of this trial is an important milestone for Boehringer Ingelheim and brings us closer to achieving our aim of transforming lives of people living with fibrotic diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The effects shown for anti-IL-11 preclinically are impressive and could, if confirmed in the clinic, herald a dramatic advance in the treatment of fibrotic diseases.”
“Enleofen is very excited to see the IL-11 inhibitor partnership with Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D, moving forward into the clinic to address unmet patient needs,” said Prof Stuart Cook, co-founder of Enleofen and Tanoto Foundation Professor of Cardiovascular Medicine at the SingHealth Duke-NUS Academic Medical Centre and the Cardiovascular & Metabolic Disorders Programme at Duke-NUS Medical School, Singapore.
The IL-11 program complements Boehringer Ingelheim’s clinical fibrotic disease pipeline portfolio which includes BI 1015550, a phosphodiesterase 4B (PDE4B) inhibitor, under investigation in two Phase III randomized, double-blind, placebo-controlled trials—FIBRONEER™-IPF (NCT05321069) and FIBRONEER™-ILD (NCT05321082)—to investigate the efficacy, safety and tolerability of BI 1015550 over at least 52 weeks in patients with IPF and in patients with other progressive fibrosing ILDs and several other clinical stage programs.
###
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com
About Enleofen
Enleofen is a Singapore-based biotech company developing first-in-class antibody therapeutics for the treatment of fibro-inflammatory human diseases. The initial discovery science and drug target validation was carried out by founders Stuart Cook and Sebastian Schäfer at the National Heart Centre Singapore at SingHealth and Duke-NUS Medical School and was subsequently licensed to Enleofen. Since 2017, the company has invested extensively in target validation, drug development, and preclinical studies, with the support of experienced international life sciences executives and investors, including founding directors Jeffrey Lu and Andrew Khoo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005762/en/
Contact information
Reinhard Malin
reinhard.malin@boehringer-ingelheim.com
Linda Ruckel
linda.ruckel@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ilsong Educational Foundation Chairman Dai-Won Yoon Wins Linnaeus Medal as the First in Asia2.6.2023 12:00:00 EEST | Press release
On May 30, Chairman Dai-Won Yoon of Ilsong Educational Foundation received the Linnaeus Medal from Uppsala University at Hallym University. This makes him the first person from Asia to receive the award. Ilsong Educational Foundation operates Hallym University and Hallym University Medical Center. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005495/en/ Chairman Dai-Won Yoon (left) of Ilsong Educational Foundation received Linnaeus Medal as the 1st in Asia (Photo: Hallym University) Chairman Yoon is the honoree of 2020. The award ceremony, which had been postponed due to COVID-19, was held this year with a delegation led by Vice Chancellor Anders Hagfeldt of Uppsala University visiting Korea. The Linnaeus Medal to commemorate Carl Linnaeus, a Swedish botanist, is awarded annually by Uppsala University to a person who has made a significant contribution to the field of science. Chairman Yoon was honored for his work in
10th Annual World Patient Safety, Science & Technology Summit Begins2.6.2023 09:15:00 EEST | Press release
Day one of the 10th Annual World Patient Safety, Science & Technology Summit presented by the Patient Safety Movement Foundation (PSMF) saw global leaders across the world of patient safety call for an increased urgency in addressing the issue of preventable harm within healthcare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601006140/en/ Joe Kiani, founder of the Patient Safety Movement Foundation, speaks at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire) Celebrating the PSMF’s 10th anniversary, Dr. Michael Ramsay, chief executive officer of the PSMF, reflected on the role that the increasing availability of hospital data on medical errors could play in reducing harm. “I’m very optimistic that we’re really going to see a difference in healthcare,” he said. “Technology is changing. We’re now getting real data. We know what the outcomes are in hospit
Autel Energy Holds Partner Summit in Amsterdam, Mapping Out Europe Strategy2.6.2023 09:00:00 EEST | Press release
Autel Energy, a leading provider of EV charging products and services, successfully hosted the Autel Partner Summit at Muziekgebouw in Amsterdam from May 31 to June 1, 2023. The event not only showcased Autel’s visionary Europe strategy for the next two years but also provided partners opportunities to gain insights into the company's vision, and learn about Autel’s new products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005428/en/ A quick afternoon bite with the Autel partners. (Photo: Business Wire) The Partner Summit helped Autel Energy to strengthen its partnerships in Europe and highlighted its collaborations with key clients. Notable partners in attendance included Maxicharger AC clients such as Sevadis and Deta, as well as Maxicharger DC clients such as Floading, Gasgas, and eWays. The company also partnered with CPO clients like Fastway and Powerdo, as well as energy companies like Enefit. The Summit was d
PL BioScience and Macopharma enter into a Patent License and Assignment Agreement regarding Human Platelet Lysate (HPL) cell culture supplements.2.6.2023 08:22:00 EEST | Press release
PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period. In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption. About PL BioScience: Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HP
AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera2.6.2023 05:00:00 EEST | Press release
With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA, PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom